ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,638.72
0.23%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. BioXcel Therapeutics Inc (BTAI)

  7. BioXcel Therapeutics Inc (BTAI) Noticias

BTAI

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BTAI
FechaHoraFuenteTítuloSímboloCompañía
28/05/202406:00GlobeNewswire Inc.BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
21/05/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202408:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202406:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202406:00GlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
25/04/202406:00GlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
24/04/202409:30GlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
22/04/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
10/04/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
25/03/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
15/03/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
12/03/202406:00GlobeNewswire Inc.BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:BTAIBioXcel Therapeutics Inc
01/03/202406:00GlobeNewswire Inc.BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
13/02/202408:00GlobeNewswire Inc.BioXcel Therapeutics Announces Termination of Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
12/02/202406:14GlobeNewswire Inc.BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)NASDAQ:BTAIBioXcel Therapeutics Inc
08/02/202416:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
08/02/202415:01GlobeNewswire Inc.BioXcel Therapeutics Announces Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
06/02/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®NASDAQ:BTAIBioXcel Therapeutics Inc
05/02/202406:00GlobeNewswire Inc.BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
22/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BTAIBioXcel Therapeutics Inc
12/01/202415:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BTAIBioXcel Therapeutics Inc
18/12/202315:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
12/12/202306:00GlobeNewswire Inc.BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day TodayNASDAQ:BTAIBioXcel Therapeutics Inc
11/12/202306:00GlobeNewswire Inc.BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage ProgramsNASDAQ:BTAIBioXcel Therapeutics Inc
30/11/202306:00GlobeNewswire Inc.BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023NASDAQ:BTAIBioXcel Therapeutics Inc
13/11/202310:59Edgar (US Regulatory)Form RW WD - Withdrawal of Registration Withdrawal RequestNASDAQ:BTAIBioXcel Therapeutics Inc
13/11/202309:23Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BTAIBioXcel Therapeutics Inc
08/11/202306:00GlobeNewswire Inc.BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma PhenotypeNASDAQ:BTAIBioXcel Therapeutics Inc
06/11/202306:00GlobeNewswire Inc.BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)NASDAQ:BTAIBioXcel Therapeutics Inc
31/10/202306:00GlobeNewswire Inc.BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:BTAIBioXcel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTAI

Su Consulta Reciente

AQEU
DFDSC
DFDS
NYSE
RBS.PRHCL
Royal Bank of Scotland Group Plc
BIT
P1YCA7
NLBNPIT1YCA7 20991231 15...
BIT
P1YNT4
NLBNPIT1YNT4 20991231 76...
USOTC
AOZOF
Aoxora Bank (PK)
TSXV
UFC
Urbanfund
COIN
BENETH
Ben
EU
EPAB
Amndi S&P Euzn PAB Net Z...
BIT
P20T09
NLBNPIT20T09 20241220 110
COIN
PLEBUST
PLEBToken
MRTX
MANAETH
Decentraland
NASDAQ
AGNCP
AGNC Investment
NASDAQ
SGC
Superior Group of Compan...
LSE
RBN
Robinson
NASDAQ
MACK
Merrimack Pharmaceuticals
TIDE
ADAUSDT
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados